For Partners
Turning research findings into diagnostics and therapies.
Biozipcode, Inc. draws on research into the proposed cell population called “diabetes stem cells” (DSCs) and on Biozipcode™ cell-targeting technology to advance new diagnostic and therapeutic technologies toward practical use.
Bringing research into healthcare takes more than scientific validation at universities and research institutions. It also requires collaboration across pharmaceuticals, diagnostics, drug delivery, clinical development, manufacturing, regulatory affairs, and informatics.
By combining our strengths with those of companies and research institutions in Japan and abroad, we build partnerships suited to each stage of research, from collaborative studies and technology licensing to joint development, business alliances, and equity partnerships.
PARTNERING WITH BIOZIPCODE
Research together. Develop together.
We aim to create new value by combining Biozipcode, Inc.’s research and technologies with partners’ expertise, drug discovery assets, research data, clinical resources, and manufacturing and development capabilities.
OUR PLATFORM
The Research Behind Our Partnerships
Biozipcode, Inc. builds partnerships primarily around the following research and technologies.
DIABETES STEM CELLS
Diabetes Stem Cell Research
We study abnormal hematopoietic stem cells and bone marrow-derived cells thought to contribute to the persistence of diabetes and its complications. “Diabetes stem cells” (DSCs) is a term used in this research.
BIOZIPCODE™
Cell-Targeting Technology
We seek short peptides that recognize specific cells and tissues and explore their use in diagnostics and drug delivery.
BIOMARKERS & DIAGNOSTICS
Biomarkers & Diagnostics
We study disease-associated cells as possible markers for patient stratification, treatment response assessment, and future companion diagnostics.
TARGETED THERAPEUTICS
Cell-Targeted Therapy
We study investigational approaches that combine Biozipcode™ with drugs, nucleic acids, genes, and other agents to deliver treatment more selectively to intended cells.
FROM DISCOVERY TO TRANSLATION
Bringing Research into Medical Practice
We value partnerships because the path from basic research to healthcare spans many areas of expertise.
DISCOVERY
Research & Discovery
↓
VALIDATION
Scientific Validation
↓
INTELLECTUAL PROPERTY
Intellectual Property
↓
PRECLINICAL DEVELOPMENT
Preclinical Development
↓
CLINICAL DEVELOPMENT
Clinical Development
↓
REGULATORY APPROVAL
Approval
↓
MEDICAL IMPLEMENTATION
Practical Application
Biozipcode, Inc. works with partners whose expertise fits each stage, with the aim of turning research findings into care that reaches patients.
WHO WE WORK WITH
Working Across Disciplines
We welcome opportunities to work with organizations such as:
Pharmaceutical & Biotech Companies
Medicines, drug candidates, preclinical development, CMC, clinical development, commercialization
Universities & Research Institutions
Disease research, target validation, basic and applied research
Medical Institutions
Human samples, patient cohorts, clinical research
Diagnostics & Medical Device Companies
Biomarkers, in vitro diagnostics (IVD), cell capture, medical devices
Drug Delivery, Nucleic Acid & Gene Therapy Companies
Payload、Vector、Drug Delivery
AI & Data Companies
NGS, bioinformatics, image analysis, AI
CRO, Manufacturing & Regulatory Partners
Preclinical studies, clinical trials, GMP manufacturing, quality and regulatory affairs
BUILD WITH US
Let’s Build New Medical Care Together.
Biozipcode, Inc. seeks partners for more than the sale of finished technologies.
We value relationships with organizations ready to develop and test hypotheses, advance technologies, and work toward practical applications for research questions that do not yet have answers.
From research to intellectual property.
From intellectual property to development.
From development to care that reaches patients.
We welcome inquiries about new research and business collaborations from universities, research institutions, pharmaceutical and biotech companies, medical institutions, and others.
